MRI Contrast Agents Market Share

On the basis of geographical analysis, the MRI contrast agents market is segmented into North America, Latin America, Europe, Asia Pacific and the Middle East & Africa regions. Asia Pacific is anticipated to dominate majority revenue share by 2036, owing to increasing necessity for advanced diagnosis method to detect various disease indications such as neurological disorders, cancer, cardiovascular diseases, and others.

North America Market Analysis

Furthermore, the MRI contrast agents market in North America is evaluated to occupy the largest share in terms of revenue in the future, on the back of the growing prevalence of chronic disorders in the region. According to the report published by the National Cancer Institute, in 2020, 1.8 million new cancer cases were registered in the United States. Such increasing number of cancer cases in the United States has significantly increased the demand for MRI examination in this region, which in turn is expected to drive the demand for MRI contrast agents in North American countries.

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of MRI contrast agents is estimated at USD 2.23 billion.

MRI Contrast Agents Market size was over USD 2.11 billion in 2023 and is anticipated to reach USD 5.02 billion by 2036, growing at around 6.9% CAGR during the forecast period i.e., between 2024-2036. Rising prevalence of chronic disorders and implementation of MRI examination of early diagnosis will fuel the market growth.

Asia Pacific is anticipated to dominate majority revenue share by 2036, owing to increasing necessity for advanced diagnosis method to detect various disease indications such as neurological disorders, cancer, cardiovascular diseases, and others.

The major players in the market include Bayer AG, GE Healthcare, LLC, Guerbet GmbH, Bracco Imaging SpA, Miltenyi Biotec B.V. & Co. Kg, and more.

MRI Contrast Agents Market Share